Related Experiment Video
Updated: Jan 9, 2026
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
piR-43452 suppresses bladder cancer progression and enhances gemcitabine sensitivity via GTSF1/PIWIL4-mediated LRP1
Yuchen Shi1, Jiazhu Sun1, Kai Yu1
1Department of Urology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Abstract:
Piwi-interacting RNAs (piRNAs), while crucial for genomic integrity in germline cells, remain poorly characterized in somatic cancers. This study identifies piR-43452 as a significantly downregulated piRNA in bladder cancer (BCa), with loss of expression correlating clinically with muscle invasion and lymph node metastasis. Through assays in vitro and in vivo, we demonstrate that piR-43452 acts as a potent tumor suppressor, inhibiting BCa cell proliferation, migration, and xenograft growth while promoting apoptosis. Mechanistically, we identified that piR-43452 directly binds the 3'UTR of LRP1 mRNA and recruits the GTSF1/PIWIL4 complex, which enhances target cleavage through GTSF1-dependent conformational activation. This post-transcriptional regulation led to significant LRP1 suppression, subsequently inhibiting proliferation and restoring chemosensitivity. Our findings establish a novel piRNA-guided mechanism for overcoming chemoresistance and suggest that targeting the piR-43452/GTSF1/PIWIL4/LRP1 axis may provide therapeutic benefit in gemcitabine-resistant BCa.
Insights
Piwi-interacting RNAs (piRNAs) like piR-43452 are downregulated in bladder cancer, acting as tumor suppressors. Restoring piR-43452 may overcome chemoresistance by targeting LRP1.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Piwi-interacting RNAs (piRNAs) are vital for germline genomic integrity but their role in somatic cancers, including bladder cancer (BCa), is not well understood.
- Dysregulation of non-coding RNAs, including piRNAs, is increasingly implicated in cancer development and progression.
Purpose of the Study:
- To investigate the role of piRNAs in bladder cancer.
- To identify specific piRNAs that are downregulated in BCa and assess their functional significance.
- To elucidate the molecular mechanism by which identified piRNAs suppress tumor growth and overcome chemoresistance.
Main Methods:
- Bioinformatic analysis to identify differentially expressed piRNAs in bladder cancer.
- In vitro cell culture assays (proliferation, migration, apoptosis) and in vivo xenograft models to evaluate tumor suppressor functions.
- RNA immunoprecipitation (RIP) and luciferase reporter assays to confirm direct binding of piR-43452 to LRP1 mRNA.
- Western blotting and qRT-PCR to assess protein and mRNA levels of LRP1 and other relevant molecules.
- Assessment of chemosensitivity in vitro and in vivo.
Main Results:
- piR-43452 was identified as a significantly downregulated piRNA in bladder cancer, with reduced expression correlating with advanced disease (muscle invasion, lymph node metastasis).
- piR-43452 demonstrated potent tumor suppressor activity by inhibiting BCa cell proliferation, migration, and xenograft tumor growth, while promoting apoptosis.
- Mechanistically, piR-43452 directly targets the 3'UTR of LRP1 mRNA, recruiting the GTSF1/PIWIL4 complex to enhance LRP1 mRNA cleavage and degradation.
- Suppression of LRP1 by piR-43452 led to reduced proliferation and restored sensitivity to gemcitabine in resistant BCa cells.
Conclusions:
- piR-43452 functions as a tumor suppressor in bladder cancer through post-transcriptional regulation of LRP1.
- The piR-43452/GTSF1/PIWIL4/LRP1 axis represents a novel mechanism for controlling tumor growth and chemoresistance in BCa.
- Targeting this axis offers a potential therapeutic strategy for gemcitabine-resistant bladder cancer.
More Related Videos
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
08:43An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
